Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Philippe Gabriel Steg,
Mr Robert Glynn
Presenter | see Discussant report
Robert Glynn, (United States of America)
List of Authors: Robert J Glynn and Paul M Ridker on behalf of the JUPITER Trial Study Group
Relationships of cholesterol levels with cardiovascular risk weaken with advancing age, and use of statins for primary prevention in older people remains controversial. Among the 17802 apparently healthy men and women randomized in the JUPITER trial, 5695 were initially age 70 years or older. The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0) on the basis of convincing evidence of efficacy with respect to the combined primary end point. We present here the observed effects of rosuvastatin in participants age 70 years or older, based on intention-to-treat analyses, for the composite primary end point and the pre-specified secondary end points of total mortality, venous thromboembolism, and incident diabetes. The 32% of participants in the JUPITER trial who were aged 70 years or older accrued 49% (N=194) of the 393 confirmed primary end points. The rates of the primary end point in this age group were 1.22 and 1.99 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio 0.61; [95% CI, 0.46 to 0.82]; P<0.001). Corresponding rates of secondary end points in this age group were 1.63 and 2.04 for any death (hazard ratio 0.80; [95% CI, 0.62 to 1.04]; P=0.090), 0.24 and 0.41 for venous thromboembolism (hazard ratio 0.58; [95% CI, 0.31 to 1.11] P=0.096), and 1.20 and 0.98 for diabetes (hazard ratio 1.21; [95% CI, 0.86 to 1.71]; P=0.27). Thus, relative effects observed in older participants were quite similar to those reported for the overall trial. However, because absolute risks were substantially higher in this age group, the estimated number needed to treat (NNT) for 5 years to prevent 1 primary end point was 19, compared with the estimated NNT of 25 for the overall trial.
Discussant | see Presenter abstract
Philippe Gabriel Steg, FESC (France)
Randomized evidence on Rosuvastatin for primary prevention in individuals 70 years of age or older. JUPITER
This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.
© 2016 European Society of Cardiology. All rights reserved